On Wednesday, June 30, 2021, CureVac N.V. (Nasdaq: CVAC) announced results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV.

The company hosted a press conference in German language on Thursday, July 1, 2021, 10:00 a.m. CEST.

The corresponding presentation slides can be found under "Downloads". An replay of the press conference can be found under "Links".